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OBJECTIVE — Glucose ﬂuctuations trigger activation of oxidative stress, a main mechanism
leading to secondary diabetes complications. We evaluated the relationship between glycemic
variability and -cell dysfunction.
RESEARCH DESIGN AND METHODS — We conducted a cross-sectional study in 59
patients with type 2 diabetes (aged 64.2  8.6 years, A1C 6.5  1.0%, and BMI 29.8  3.8
kg/m
2 [mean  SD]) using either oral hypoglycemic agents (OHAs) (n  34) or diet alone
(nonusers). As a measure of glycemic variability, the mean amplitude of glycemic excursions
(MAGE) was computed from continuous glucose monitoring data recorded over 3 consecutive
days. The relationships between MAGE, -cell function, and clinical parameters were assessed
by including postprandial -cell function (PBCF) and basal -cell function (BBCF) obtained by
a model-based method from plasma C-peptide and plasma glucose during a mixed-meal test as
wellashomeostasismodelassessmentofinsulinsensitivity,clinicalfactors,carbohydrateintake,
and type of OHA.
RESULTS — MAGE was nonlinearly correlated with PBCF (r  0.54, P  0.001) and with
BBCF (r  0.31, P  0.025) in OHA users but failed to correlate with these parameters in
nonusers (PBCF P  0.21 and BBCF P  0.07). The stepwise multiple regression analysis
demonstrated that PBCF and OHA combination treatment were independent contributors to
MAGE (R
2  0.50, P  0.010), whereas insulin sensitivity, carbohydrate intake, and nonglyce-
mic parameters failed to contribute.
CONCLUSIONS — PBCFappearstobeanimportanttargettoreduceglucoseﬂuctuationsin
OHA-treated type 2 diabetes.
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O
f genetic and environmental origin,
defective insulin secretion and in-
sulinsensitivityarethemainfactors
causingthedevelopmentandprogression
of type 2 diabetes. The UK Prospective
Diabetes Study (UKPDS) showed that af-
ter an initial improvement, glycemic con-
trol continues to deteriorate despite the
use of oral agents to enhance insulin se-
cretion and to reduce insulin resistance
(1).Thisdeteriorationcanbeattributedto
the progressive decline of -cell function.
Eveninsubjectswithwell-controlledtype
2 diabetes, 70% of the variability of A1C
can be explained by abnormalities in
postprandial glucose (2). Chronic sus-
tained hyperglycemia has been shown to
exertdeleteriouseffectsonthe-cellsand
the vascular endothelium (3). Monnier et
al. (4) and Brownlee and Hirsch (5) have
recentlyemphasizedthatanothercompo-
nent of dysglycemia, i.e., glycemic vari-
ability, is even more important than
chronic sustained hyperglycemia in gen-
erating oxidative stress and contributing
to the development of secondary diabetes
complications. In vivo studies have con-
vincingly demonstrated that hyperglyce-
mic spikes induce increased production
of free radicals and various mediators of
inﬂammation, leading to dysfunction of
boththevascularendothelium(3)andthe
pancreatic -cell (6). Furthermore, by
evaluating hard end points in prospective
analyses,Shiraiwaetal.(7)andCavalotet
al. (8) have reported deleterious effects of
glucose excursions on diabetic vascular
complications.
Prolonged postprandial glucose ex-
cursions have been linked to several fac-
tors such as inadequate insulin secretion,
insulin deﬁciency, or an abnormal release
ofcounterregulatoryhormones(9).How-
ever, glycemic variability in type 2 diabe-
tes appears to result from the complex
interplaybetweenpathophysiologicalfac-
tors and behavioral and treatment factors
(10).
In clinically established type 2 diabe-
tes, the degree of association of glycemic
variability with pancreatic -cell dys-
function remains unclear. To address this
issue, we used continuous glucose moni-
toring to assess glycemic variability and
used an insulin secretion model during a
mixed-meal test (MMT) to measure basal
-cell function (BBCF) and postprandial
-cell function (PBCF) in subjects with
type 2 diabetes after withdrawal of oral
hypoglycemic agents or treated with diet
alone.
RESEARCH DESIGN AND
METHODS— This cross-sectional
studyenrolled59consecutiveoutpatients
with type 2 diabetes. All patients were
Caucasians and were recruited from
seven practices of primary care physi-
cians/internists in the district of Greif-
swald, Germany, from 2004 to 2006.
Their antihyperglycemic therapy con-
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(OHAs), either sulfonylurea (n  12) and
metformin (n  10) alone or a combina-
tionofboth(n12),orofdietalone(n
25). None were taking other medications
known to alter glucose metabolism, and
all were otherwise in good health.
Criteriaforinclusionwereadiagnosis
of type 2 diabetes for at least 1 year but
20 years, age 35–79 years, BMI of
24–38 kg/m
2, A1C of 5.0–9.0%, and
treatment with OHAs or diet. Exclusion
criteria were need for insulin use; circu-
lating islet cell antibodies; concomitant
chronic disease, including kidney, liver,
and cardiovascular disease; recent acute
illness; or changes in diet, treatment, or
lifestylewithin3monthsbeforetheinclu-
sion examination.
Before commencement of the study
procedures, OHA medication was with-
drawn and substituted with placebo for 8
days to allow for the pharmacological ef-
fects of sulfonylureas and metformin to
dissipate (11,12), taking into account the
possibility that a more prolonged with-
drawal might cause deleterious effects on
glucose control. During the OHA with-
drawal and the 4-day study period, sub-
jects were under medical supervision and
were advised to continue their regular
lifestyle and to maintain their usual exer-
cise and dietary patterns.
The study protocol was approved by
the ethics review board at the University
of Greifswald, Greifswald, Germany, and
was conducted in accordance with the
rules in the European Community and
the Declaration of Helsinki. Written in-
formed consent was obtained from all
study participants.
Study procedures
At study entry, a continuous glucose
monitoring (CGM) system (CGMS) sen-
sor (Medtronic MiniMed, Northridge,
CA) was inserted and calibrated accord-
ing to the standard operating guidelines,
and CGM was performed for 60  10 h
(mean  SD). At day 2 of the study, fol-
lowing a 12-h overnight fast, a 500-ml
standardized liquid MMT, containing
75 g carbohydrate, 58 g fat, and 30 g pro-
tein to total 1,000 kcal (caloric contribu-
tion: 37% carbohydrate, 51% fat, and
12% protein) (13), was given at the phy-
sician’s practice as described previously
(14). Patients were required to consume
the test meal within 10–15 min. Stan-
dardization of diet was not performed
during CGMS measurements, but sub-
jects entered type and amount of food
consumed into their logbooks. Blood
samples were taken via an indwelling in-
travenous cannula, which was inserted
into an arm vein, at 15, 0, 30, 60, 90,
120, and 150 min relative to the meal in-
gestion for the measurement of glucose
and C-peptide.
Blood drawn for measurement of
standardlaboratoryvalueswasshippedto
a central laboratory, where A1C was ana-
lyzedbytheBio-RadDiamatanalyzersys-
tem using ion-exchange high-
performance liquid chromatography
(normal range 4.6–6.0%). Plasma glu-
cosewasmeasuredbytheglucoseoxidase
enzymatic method on a DiaSys Super G
Analyzer (Hitado Diagnostic Systems,
Moehnesee-Delecke, Germany). The
MedicalDiagnosticLaboratoryattheUni-
versityofGreifswaldperformedserumin-
sulin (INS enzyme immunoassay; IBL,
Hamburg, Germany) and C-peptide anal-
yses (HCP enzyme immunoassay, DPC
Biermann, Bad Nauheim, Germany).
Cross-reactivity of the insulin antibody
with human proinsulin was 3% and with
the C-peptide antibody was 17%.
CGM data and glycemic variability
Subjects used home blood glucose moni-
tors that were calibrated with Accu-Chek
glucose standards (Roche Diagnostics,
Mannheim, Germany) and entered at
least four glucometer readings per day
into the CGMS monitor for calibration.
TheglucoseproﬁlesobtainedfromCGMS
measurements were analyzed using
MiniMed Solution Software (Medtronic
MiniMed). Proﬁles with less than four
glucometer entries were disregarded.
Mean sensor glucose, sensor glucose
range, median sensor glucose, and the
times patients were hyperglycemic (10
mmol/l) and hypoglycemic (3.3
mmol/l) were calculated from the CGMS
datasets.Thevalue10.0mmol/lastheup-
per limit of glucose at postprandial times
was chosen according to recommenda-
tions of the American Diabetes Associa-
tion (15). The area under the curve for
sensor glucose (AUCCGM) was calculated
with the trapezoidal method for a 24-h
time period. MAGE, considered as the
“gold standard” of glycemic variability,
was calculated as described by Service et
al.(16)fromtheglucoseexcursionsofthe
CGMS proﬁles. Carbohydrate intake
(breadexchangeunits)perdaywascalcu-
latedfromthesubjects’logbooks,accord-
ing to standard tables containing the
nutrient composition with bread ex-
change units for diabetic subjects.
Glucose and insulin levels during
MTT
Fastingglucoseandfastingplasmainsulin
were obtained as mean values of pretest
MMT measurements. The difference be-
tweenfastingandpeakplasmaconcentra-
tions of glucose and insulin during the
MMT are denoted as incremental glucose
and insulin peak, respectively. The incre-
mental areas under the curve (IAUCs) for
glucose and insulin were calculated with
the trapezoidal method for the 0- to 150-
min postmeal time interval.
Model of C-peptide kinetics during
MTT
BBCFandPBCFwereestimatedfromglu-
cose and C-peptide time-concentration
proﬁles during the MMT using an insulin
secretion model validated in healthy sub-
jects and subjects with newly diagnosed
type 2 diabetes (17). The model parame-
ters M0 and MI were estimated using
weighted nonlinear regression analysis
(18). M0 is an index of the BBCF and rep-
resents the ability of fasting glucose to
stimulate-cells.Itiscalculatedasfasting
C-peptide secretion (per unit volume of
the central compartment) divided by fast-
ing plasma glucose concentration.
MIisanindexofPBCFandrepresents
the ability of postprandial glucose to
step up -cell secretion. It equals the
increment in secretion (again per unit
volume of the central compartment) in
response to a unit increment in glucose
concentration.
Insulin sensitivity
Insulin sensitivity was calculated from
duplicate fasting insulin and fasting glu-
cose samples using the computer pro-
gram for the homeostasis model
assessment (HOMA2) of insulin resis-
tance (19).
Statistical analysis
The variables are summarized either as
means  SD or as medians (25th–75th
percentile) as appropriate. Differences in
baseline clinical and biochemical charac-
teristics were tested using an unpaired t
test. Spearman correlation analysis and
nonlinear regression were performed to
relate glycemic variability to -cell func-
tion. The stepwise multiple regression
analysis was used to explore the inﬂuence
of -cell function on MAGE including
various clinical factors. The variables
were tested for normality and, where ap-
propriate, were logarithmically trans-
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considered statistically signiﬁcant.
RESULTS
Clinical and biochemical
characteristics
Of the 69 subjects with type 2 diabetes
who volunteered for the study, 10 were
excluded: 2 tested positive for GAD anti-
bodies, 3 aborted CGMS measurements,
and 5 refused the MMT. The 59 partici-
pating subjects were grouped into OHA
users and nonusers. As shown in Table 1,
diabetes duration was signiﬁcantly longer
andA1CwashigherinOHAusersthanin
nonusers. All other characteristics, in-
cluding carbohydrate intake during the
study, were not signiﬁcantly different be-
tween the treatment groups.
CGMS measurements and glycemic
variability
Table 2 shows the results of CGM mea-
surements.Allsensorglucosevalueswere
signiﬁcantly higher in OHA users than in
nonusers. Likewise, between-group dif-
ferenceswereobservedintheglucosearea
values (mean AUCCGM). Compared with
the OHA users, nonusers spent a signiﬁ-
cantly lower amount of time in the hyper-
glycemic range (10.3 vs. 0.9 h/day, P 
0.001), whereas the duration of hypogly-
cemia was almost negligible. The MAGE
was signiﬁcantly higher in the group of
OHA users than in nonusers and ex-
ceeded the proposed 4 mmol/l target
level.
Plasma glucose, plasma insulin, and
estimates of pancreatic -cell
function during the MMT
The statistical comparisons of measure-
ments characterizing the glycemic status,
-cell function, and insulin sensitivity are
summarized in Table 2. Fasting glucose,
the incremental glucose peak, and
IAUC for glucose were signiﬁcantly
higher in OHA users than in nonusers
duringtheMMT.Althoughfastinginsu-
lin levels, incremental insulin peak, and
IAUC for insulin were not signiﬁcantly
different between the two subject
groups, IAUCInsulin/IAUCGlucose was
signiﬁcantly decreased in OHA users
(171.3 pmol   l
1   150 min
1, P 
0.010).
Relationships between glycemic
variability and -cell function
When the relationship between MAGE
and -cell function was analyzed by non-
linear regression analysis, including both
OHA users and nonusers, a signiﬁcant re-
lationship was found with the model in-
dexes of -cell function. As shown in Fig.
1, the relationships of MAGE with PBCF
as a group (r  0.66, P  0.001) and
BBCF (r  0.44, P  0.001) were nonlin-
ear and a decrease in PBCF 25  10
9/
min was associated with a steep increase
in MAGE. A separate analysis of the two
subject groups showed that the relation-
ship between MAGE and PBCF remained
signiﬁcant for OHA users (r  0.54, P 
0.001) but failed to achieve signiﬁcance
for nonusers (r  0.26, P  0.21). A sta-
tistically signiﬁcant nonlinear association
was also observed with BBCF in OHA us-
ers (r  0.39, P  0.025) but not in non-
users(r0.37,P0.07).MAGEdidnot
correlate with fasting insulin (r  0.08,
Table 1—Clinical characteristics of the study groups
OHA users Nonusers P value
n 34 25
Sex (male/female) 15/19 16/9 0.13
Age (years) 65.0 (57.0–71.0) 8.5 64.0 (62.0–69.0) 0.65
Diabetes duration (years) 8.5 (3.0–11.0) 2.0 (1.0–6.0) 0.003
First-degree relatives with diabetes 13 (37) 13 (52)
BMI (kg/m
2) 29.5  3.9 30.2  3.6 0.42
Waist circumference (cm) 101.2  12.6 103.8  12.5 0.45
Blood pressure (mmHg)
Systolic 140.0 (125.0–145.0) 130.0 (130.0–142.5) 0.98
Diastolic 80.0 (80.0–90.0) 80.0 (80.0–86.3) 0.39
A1C (%) 6.8  1.2 6.1  0.6 0.013
Fasting C-peptide (nmol/l) 0.92 (0.70–1.26) 0.91 (0.71–1.25) 0.90
Triglyceride (mmol/l) 1.8 (1.3–2.5) 1.8 (1.5–2.2) 0.57
HDL cholesterol (mmol/l) 1.3 (1.1–1.4) 1.4 (1.0–1.6) 0.45
Carbohydrate intake (BU/day) 10.0 (9.3–12.5) 12.0 (10.0–14.0) 0.14
Data are means  SD, medians (25th–75th percentile), or n (%). Signiﬁcance level OHA users vs. nonusers,
P 0.05. BU, bread exchange units.
Table 2—CGM data, glycemic variability, MMT-derived parameters, and insulin sensitivity
OHA user Nonusers P value
CGM data
Mean sensor glucose (mmol/l) 9.8 (8.6–13.1) 7.0 (6.2–7.6) 0.001
Mean sensor glucose range (mmol/l) 8.7  2.5 5.8  2.3 0.001
Median sensor glucose (mmol/l) 9.7 (8.2–12.8) 6.8 (6.2–7.9) 0.001
Mean AUCCGM (mmol   l
1   24 h
1) 236.0 (207.6–313.7) 166.8 (147.6–184.8) 0.001
Duration of hyperglycemia (h/day) 10.3 (5.7–20.9) 0.9 (0.0–2.4) 0.001
Duration of hypoglycemia (h/day) 0.0 (0.0–1.2) 0.0 (0.0–0.0) 0.033
Glycemic variability
MAGE (mmol/l) 5.7  1.8 3.6  1.9 0.001
MMT-derived parameters
Fasting glucose (nmol/l) 8.1 (7.4–11.5) 7.0 (6.0–7.8) 0.001
Incremental glucose peak (mmol/l) 4.2 (3.3–4.8) 2.4 (1.6–3.2) 0.001
IAUCGlucose (mmol   l
1   150 min
1) 254.5 (187.0–305.0) 117.5 (54.5–156.5) 0.001
Fasting plasma insulin (nmol/l) 0.11 (0.07–0.14) 0.10 (0.09–0.13) 0.77
Incremental insulin peak (mmol/l) 0.55 (0.27–0.81) 0.67 (0.45–0.80) 0.62
IAUCInsulin (mmol   l
1   150 min
1) 38.0 (25.0–42.9) 43.8 (21.5–44.9) 0.06
Fasting -cell function (10
9/min) 7.1 (4.9–8.8) 9.0 (8.1–11.1) 0.005
Postprandial -cell function (10
9/
min)
27.4 (15.7–46.3) 71.4 (50.4–108.8) 0.001
Insulin sensitivity
HOMA-%S 44.6  17.1 53.0  13.1 0.045
DataaremeansSDormedian(25th–75thpercentiles).SigniﬁcancelevelOHAusersvs.nonusersP0.05.
HOMA-%S, homeostatic model assessment insulin sensitivity index.
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0.01, P  0.93).
Multivariate regression analysis with
MAGE as the dependent variable
Multivariateregressionanalyseswereper-
formed to assess the independent effects
of -cell function as well as glycemic and
other factors on MAGE. These included
A1C,thedegreeofinsulinsensitivity,age,
sex, duration of diabetes, carbohydrate
consumption(breadexchangeunits),and
OHA therapy. Because PBCF and BBCF
are highly correlated, two independent
models were tested: model 1 including
PBCF and model 2 including BBCF. The
results of the stepwise regression analyses
are provided in Table 3. The log-
transformedPBCFwasthestrongestinde-
pendent contributor to MAGE, whereas
the sulfonylurea plus metformin combi-
nation treatment accounted for a smaller
portion of the variability. The other inde-
pendent variables failed to enter. The
BBCF substitution for PBCF in model 2
showed that only the type of OHA treat-
ment,ofwhichthesulfonylureaplusmet-
formincombinationtherapywasthemost
inﬂuential,remainedindependentlyasso-
ciated with MAGE. The basal -cell func-
tion, BBCF, and other factors did not
enter this model.
CONCLUSIONS— Data in the liter-
ature suggest a relationship between glu-
cose ﬂuctuations during postprandial
periods and the development of diabetes-
related macrovascular complications
(20). Although of unclear etiology, the
failing -cell function unequivocally con-
tributes to the glycemic instability (21).
However, the degree of association be-
tween glycemic variability and -cell
function in type 2 diabetes remains un-
clear.Thepresentstudywasperformedto
investigate these relationships using the
CGMS to determine glycemic variability
and using the insulin secretion model
(17)todetermine-cellfunction.Ourre-
sults show that in a carefully investigated
cohortofprimarycaresubjectswithfairly
well-controlled type 2 diabetes, glycemia
in the segment of OHA users is character-
ized by MAGE values above the proposed
target of 4.0 mmol/l (22) and higher-
than-recommended glucose levels after a
standard meal (15). The values for PBCF
andBBCFinourstudyareconsistentwith
datafrompreviousstudies(17).Although
the immediate pharmacological effects of
OHAs could be washed out, post hoc ex-
ploratory analysis (unpublished results)
revealed that 4 weeks after resumption of
OHA therapy, median PBCF values were
still 26% lower (P  0.047) than before
the 8-day OHA withdrawal period and
were signiﬁcantly lower compared with
those for OHA nonusers (P  0.001).
This result suggests that the increased
glucose levels during the period of OHA
withdrawalexertedalongerlastinggluco-
toxic effect on the -cell. Because we in-
vestigated the association between -cell
function and glycemic variability after
OHAwithdrawal,evenifthesubjectsmay
havenotbeenatbaseline,thisobservation
does not directly affect the relationship
between these parameters.
Wedemonstratefortheﬁrsttimethat
glycemic variability strongly correlates
with PBCF in a segment of type 2 diabetic
patients using OHAs and that the rela-
tionship is nonlinear. Our results extend
knowledge about postprandial insulin se-
cretion and glucose control. In newly di-
agnosed type 2 diabetes, Albarrak et al.
(23) showed that glucose meal responses
correlatewithpostprandial-cellrespon-
siveness but not with insulin resistance.
The nonlinear relationship between the
MAGE and PBCF suggests that, in OHA
users, postprandial -cell response at or
25  10
9/min is associated with a
drastic increase in glycemic variability,
whereas above this threshold, glycemic
variability is improved and affected by
other factors apart from -cell dysfunc-
tion. Using multivariate regression mod-
els,wefoundthatPBCFexplained44%of
the interindividual glycemic variability.
As expected, the type of OHAs was also
independently associated with MAGE.
Unexpectedly, other factors such as dia-
betes duration, insulin sensitivity, and
carbohydrate intake failed to enter the re-
gression models.
Figure 1—The relationship between MAGE and PBCF in OHA users (r  0.54, P  0.001) and
nonusers (r  0.26, P  0.21) with type 2 diabetes. The overall regression line was obtained by
nonlinear regression analysis as y  1.7435 ln(x) 	 11.208 (r  0.66, P  0.001). E, OHA
users; F, nonusers.
Table 3—Results of stepwise forward regression analysis with MAGE as the dependent
variable
Explanatory variable
Regression
coefﬁcient () SEM P value
Coefﬁcient of
determination (R
2)
Model 1
Postprandial -cell function 2.928 0.616 0.001 0.443
SU 	 MET treatment 1.610 0.607 0.010 0.504
Model 2
SU 	 MET treatment 4.020 0.572 0.001 0.307
SU treatment 2.106 0.517 0.001 0.398
MET treatment 1.575 0.491 0.002 0.491
Variables of -cell function were log transformed to assure normality. MET, metformin; SU, sulfonylurea.
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cose excursions could not be fully eluci-
datedbytheexplanatoryvariablesincluded
in the present study. It appears that other
genetic and environmental factors such as
treatmentdurationandmedicationcompli-
ance may be responsible for the residual
amount of unexplained variability. How-
ever,theinﬂuenceofthesefactorsisdifﬁcult
toassessinacross-sectionalstudyforwhich
the primary aim is to investigate the rela-
tionship between MAGE and -cell dys-
function. These environmental factors are
associated with glycemic variability and
most likely with postprandial hyperglyce-
mia as has been recently demonstrated in
insulin-treated type 2 diabetes (24). Al-
though the subjects in the present study
consumed comparable amounts of carbo-
hydrate and underwent a standardized
MMT,itwasbeyondthescopeofourinves-
tigation to analyze medication compliance
or other behavioral factors in detail.
A weakness of the current study is its
cross-sectional nature. The strengths of
the study include CGM measurements,
use of a standardized MMT, and central
laboratory analyses.
In summary, we demonstrate a non-
linearrelationshipbetweenglycemicvari-
ability and -cell dysfunction in a
segment of type diabetic patients using
OHAs.ThePBCFcorrelatesmoststrongly
with glycemic variability. Our data sug-
gest that PBCF is an important thera-
peutic target in controlling glucose
excursions during postprandial periods
to prevent secondary complications of
type 2 diabetes. In this regard, treatment
regimens including incretin mimetics
(22,25) might have the potential of longer-
term improvement in PCBF.
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